PH31400A - Cycloalkano-indole and azaindole derivatives. - Google Patents

Cycloalkano-indole and azaindole derivatives.

Info

Publication number
PH31400A
PH31400A PH51415A PH51415A PH31400A PH 31400 A PH31400 A PH 31400A PH 51415 A PH51415 A PH 51415A PH 51415 A PH51415 A PH 51415A PH 31400 A PH31400 A PH 31400A
Authority
PH
Philippines
Prior art keywords
opt
substd
alkyl
phenyl
alkoxy
Prior art date
Application number
PH51415A
Other languages
English (en)
Inventor
Muller Ulrich
Bischoff Siegfried Hilmar
Denzer Dirk
Grutzmann Rudi
Domdeybette Anke
Connell Richard
Beuck Martin
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PH31400A publication Critical patent/PH31400A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PH51415A 1994-10-04 1995-10-03 Cycloalkano-indole and azaindole derivatives. PH31400A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4435477A DE4435477A1 (de) 1994-10-04 1994-10-04 Cycloalkano-indol- und -azaindol-derivate

Publications (1)

Publication Number Publication Date
PH31400A true PH31400A (en) 1998-10-29

Family

ID=6529939

Family Applications (1)

Application Number Title Priority Date Filing Date
PH51415A PH31400A (en) 1994-10-04 1995-10-03 Cycloalkano-indole and azaindole derivatives.

Country Status (36)

Country Link
US (6) US5684014A (sv)
EP (1) EP0705831B1 (sv)
JP (1) JP3901234B2 (sv)
KR (1) KR100355986B1 (sv)
CN (2) CN1183111C (sv)
AT (1) ATE255580T1 (sv)
AU (1) AU700609B2 (sv)
CA (1) CA2159546C (sv)
CZ (1) CZ291348B6 (sv)
DE (2) DE4435477A1 (sv)
DK (1) DK0705831T3 (sv)
DZ (1) DZ1934A1 (sv)
EE (1) EE03527B1 (sv)
ES (1) ES2211890T3 (sv)
FI (2) FI113048B (sv)
HK (1) HK1005139A1 (sv)
HN (1) HN1995009160A (sv)
HR (1) HRP950505B1 (sv)
HU (1) HU225052B1 (sv)
IL (3) IL129641A0 (sv)
MA (1) MA23683A1 (sv)
MY (1) MY117282A (sv)
NO (1) NO305365B1 (sv)
NZ (1) NZ280130A (sv)
PH (1) PH31400A (sv)
PL (1) PL183154B1 (sv)
PT (1) PT705831E (sv)
RU (1) RU2157803C2 (sv)
SG (1) SG63528A1 (sv)
SI (1) SI0705831T1 (sv)
SK (1) SK284260B6 (sv)
SV (1) SV1995000062A (sv)
TN (1) TNSN95098A1 (sv)
TW (1) TW448175B (sv)
UA (1) UA44700C2 (sv)
ZA (1) ZA958297B (sv)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19525028A1 (de) * 1995-07-10 1997-01-16 Bayer Ag Amide und Sulfonamide von heterocyclisch substituierten Benzylaminen
DE19613549A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
EP0802192A1 (de) * 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19615119A1 (de) 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide
DE19619950A1 (de) 1996-04-17 1997-10-23 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
IL139203A0 (en) * 1998-05-01 2001-11-25 Lilly Co Eli Spla2 inhibitor ester
DE69914563T2 (de) 1998-10-30 2004-12-16 Eli Lilly And Co., Indianapolis Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
WO2000071502A1 (fr) * 1999-05-25 2000-11-30 Yamanouchi Pharmaceutical Co., Ltd. Derives d'hydrazide
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
DE60141895D1 (de) * 2000-03-15 2010-06-02 Sanofi Aventis Deutschland Substituierte beta-carboline mit ikb-kinase hemmender wirkung
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
AU2001244635A1 (en) * 2000-03-30 2001-10-15 Yamanouchi Pharmaceutical Co..Ltd. Hydrazide derivatives
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
CA2438582C (en) * 2001-01-31 2012-06-26 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
BR0306292A (pt) * 2002-02-28 2004-08-24 Japan Tobacco Inc Composto de éster e uso medicinal do mesmo
JPWO2003101983A1 (ja) * 2002-05-31 2005-09-29 アステラス製薬株式会社 テトラヒドロピラン誘導体
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
WO2005051382A1 (ja) * 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005230397B2 (en) * 2004-04-09 2010-04-08 Elanco Animal Health Ireland Limited Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP1806149A4 (en) * 2004-10-25 2012-12-05 Japan Tobacco Inc SOLID MEDICINAL PREPARATION IMPROVED IN TERMS OF SOLUBILITY AND STABILITY AND METHOD FOR PRODUCING SAME
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
CA2626422A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2652751A1 (en) * 2006-05-18 2007-11-29 Bayer Healthcare Ag Pharmaceutical compositions and methods of using same
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
DK2326638T5 (da) * 2008-08-06 2014-01-13 Pfizer Ltd Diazepin- og diazocan-forbindelser som mc4-agonister
JP6721499B2 (ja) 2013-03-14 2020-07-15 オステオーク インコーポレイティド 骨の成長を促進するためのアルキルアミンハルミン誘導体
US10759792B2 (en) 2014-09-05 2020-09-01 The Johns Hopkins University CaMKII inhibitors and uses thereof
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
CN110467560A (zh) * 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
BR112021002655A2 (pt) 2018-08-14 2021-05-04 Osteoqc Inc. compostos flúor ss-carbolina
BR112021002614A2 (pt) 2018-08-14 2021-05-04 Osteoqc Inc. compostos pirrol-dipiridina

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH501623A (de) * 1967-12-18 1971-01-15 Ruetgerswerke Ag Verfahren zur Herstellung von 2-Chlorpyridin und seinen Derivaten
ATE61047T1 (de) * 1986-01-23 1991-03-15 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
CA1326030C (en) * 1987-07-21 1994-01-11 John W. Gillard Cyclohept[b]indolealkanoic acids
GB9101375D0 (en) * 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
DE4308788A1 (de) * 1993-03-18 1994-09-22 Bayer Ag Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19613549A1 (de) 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615119A1 (de) * 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide

Also Published As

Publication number Publication date
UA44700C2 (uk) 2002-03-15
EE9500071A (et) 1996-04-15
FI20002693A (sv) 2000-12-08
SK123995A3 (en) 1996-06-05
DE59510839D1 (de) 2004-01-15
CZ291348B6 (cs) 2003-02-12
SV1995000062A (es) 1996-07-10
HUT73240A (en) 1996-07-29
EP0705831A2 (de) 1996-04-10
CA2159546A1 (en) 1996-04-05
PL310756A1 (en) 1996-04-15
TW448175B (en) 2001-08-01
FI108791B (sv) 2002-03-28
SI0705831T1 (en) 2004-02-29
CZ256795A3 (en) 1996-04-17
US6265431B1 (en) 2001-07-24
CN1050605C (zh) 2000-03-22
MY117282A (en) 2004-06-30
ZA958297B (en) 1996-05-06
NZ280130A (en) 1996-05-28
HN1995009160A (es) 2000-04-24
NO953930L (no) 1996-04-09
IL129641A (en) 2000-08-31
DZ1934A1 (fr) 2002-02-17
US20020147209A1 (en) 2002-10-10
DK0705831T3 (da) 2004-04-05
KR100355986B1 (ko) 2003-01-06
EE03527B1 (et) 2001-10-15
AU3292095A (en) 1996-04-18
TNSN95098A1 (fr) 1996-02-06
HRP950505B1 (en) 2002-04-30
HK1005139A1 (en) 1998-12-24
JP3901234B2 (ja) 2007-04-04
US6245775B1 (en) 2001-06-12
CA2159546C (en) 2010-12-14
NO305365B1 (no) 1999-05-18
PL183154B1 (pl) 2002-05-31
US6479503B2 (en) 2002-11-12
MA23683A1 (fr) 1996-07-01
EP0705831B1 (de) 2003-12-03
HU9502891D0 (en) 1995-11-28
US20030149073A1 (en) 2003-08-07
IL115493A0 (en) 1996-01-19
RU2157803C2 (ru) 2000-10-20
SG63528A1 (en) 1999-03-30
ATE255580T1 (de) 2003-12-15
CN1130631A (zh) 1996-09-11
FI954681A0 (sv) 1995-10-02
CN1224715A (zh) 1999-08-04
SK284260B6 (sk) 2004-12-01
US5684014A (en) 1997-11-04
AU700609B2 (en) 1999-01-07
PT705831E (pt) 2004-04-30
IL129641A0 (en) 2000-02-29
JPH08225526A (ja) 1996-09-03
HU225052B1 (en) 2006-05-29
ES2211890T3 (es) 2004-07-16
DE4435477A1 (de) 1996-04-11
FI954681A (sv) 1996-04-05
FI113048B (sv) 2004-02-27
US6858622B2 (en) 2005-02-22
CN1183111C (zh) 2005-01-05
IL115493A (en) 1999-10-28
KR960014126A (ko) 1996-05-22
HRP950505A2 (en) 1997-08-31
EP0705831A3 (de) 1997-01-22
US20020055635A1 (en) 2002-05-09
NO953930D0 (no) 1995-10-03

Similar Documents

Publication Publication Date Title
PH31400A (en) Cycloalkano-indole and azaindole derivatives.
PL310460A1 (en) Novel derivatives of imidazopyridine, method of obtaining them and drugs containing such derivatives
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
HU9600914D0 (en) 4-indolylpiperazinyl derivatives
ATE197794T1 (de) Benzyloxy-substituierte phenylglycinolamide als arzneimittel
AU6193196A (en) Substituted 4H-pyrans